Anticancer effect of PMEDAP--monitoring of apoptosis
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
10810395
Knihovny.cz E-resources
- MeSH
- Adenine analogs & derivatives therapeutic use MeSH
- Antineoplastic Agents therapeutic use MeSH
- Apoptosis drug effects MeSH
- Immunohistochemistry MeSH
- Karyotyping MeSH
- In Situ Nick-End Labeling MeSH
- Rats MeSH
- Lymphoma, T-Cell drug therapy genetics pathology MeSH
- Chromosome Mapping MeSH
- Tumor Suppressor Protein p53 analysis MeSH
- Rats, Sprague-Dawley MeSH
- Proto-Oncogene Proteins c-bcl-2 analysis MeSH
- Trisomy MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine MeSH Browser
- Adenine MeSH
- Antineoplastic Agents MeSH
- Tumor Suppressor Protein p53 MeSH
- Proto-Oncogene Proteins c-bcl-2 MeSH
Antitumor effect of N-9-[2-(phosphonomethoxy) ethyl]-2,6-diaminopurine (PMEDAP) was studied in an in vivo model of s.c. transplanted Sprague-Dawley (SD/cub) rat T-cell lymphomas. Three individual SD/cub neoplasias (SD10/96, SD14/97, SD1/90) of different phenotypes were used. During the treatment, survival of the rats, increase of lymphoma mass, and DNA fragmentation detected by APO/BRDU kit, as well as Bcl2 and p53 protein expression, were followed. The study gives evidence of the positive therapeutic effect of PMEDAP in two of the three tested lymphomas, SD10/96 and SD14/97. Slowly growing SD1/90 lymphoma differs from the others in a uniform karyotype with trisomy of chromosome 11, CD4- immunophenotype, heterogeneous cellular morphology and constitutive expression of p53 protein found in some neoplastic cells. Thus, the diverse anticancer efficacy of PMEDAP treatment among SD/cub lymphomas could be associated with the different phenotypes of individual neoplasias.
